Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

91.74 +1.13 (+1.25%)
Streaming Delayed Price Updated: 1:27 PM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
74 75 Next >
News headline image
SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis
From AstraZeneca
Via Business Wire
News headline image
GSK Stock Climbs After-Hours On $30B US Investment Pledge As Trump Pressures Big Pharma To Build In America ↗
The plan includes $1.2 billion for a new biologics factory in Upper Merion, Pennsylvania, along with AI upgrades and expanded drug production across existing U.S. sites. 
Via Stocktwits
Topics Artificial Intelligence Government World Trade
News headline image
AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit ↗
AstraZeneca pauses its £200 million UK investment as rising costs, undervaluation, and unclear policies hinder pharma R&D and foreign capital inflows. 
Via Benzinga
Topics Government
News headline image
The Weight of Progress: A New Era Dawns for Anti-Obesity Drugs, Reshaping Markets and Health
The global anti-obesity drug market is experiencing an unprecedented surge, driven by groundbreaking advancements in pharmacotherapy, particularly the advent of highly effective GLP-1 receptor... 
Via MarketMinute
Retail Buzz Builds As AstraZeneca’s Tagrisso Combo Extends Lung Cancer Survival To Nearly 4 Years ↗
Via Stocktwits
News headline image
Merck's Exit Highlights UK Risks Losing Pharma Investment Amid Rising Costs ↗
Pharmaceutical companies are pulling investment from the UK as NHS drug spending falls and pricing disputes worsen. 
Via Benzinga
News headline image
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order ↗
Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs. 
Via Investor's Business Daily
Topics Government
News headline image
FDA Expands Approval For AstraZeneca's Drug For Pediatric Patients With Rare Type Of Cancer ↗
The FDA approved AstraZeneca's Koselugo for children 1+ with NF1 and inoperable nerve tumors, expanding treatment options with an established safe dose. 
Via Benzinga
News headline image
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz ↗
Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential... 
Via Benzinga
Topics ETFs Government
Fibrogen Gets Regulator’s Green Light To Sell China Unit To AstraZeneca ↗
Via Stocktwits
News headline image
AstraZeneca Lung Cancer Combo Extends Patient Survival By Years In Key Study ↗
AstraZeneca's Tagrisso with chemotherapy improved survival in advanced NSCLC, extending median overall survival by nearly 10 months over monotherapy. 
Via Benzinga
News headline image
Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again ↗
The company is working on a treatment for an autoimmune disease that affects the muscles. 
Via Investor's Business Daily
News headline image
These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts ↗
Experts who follow these stocks think they can fly higher despite already gaining over 100% since the end of July. 
Via The Motley Fool
News headline image
TAGRISSO® (osimertinib) plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca, Corning And More On CNBC's 'Final Trades' ↗
On CNBC's “Halftime Report Final Trades,” Jim Lebenthal, partner at Cerity Partners, named AstraZeneca PLC (NASDAQ:AZN) as his 
Via Benzinga
News headline image
Market Jitters: Wall Street Braces for Continued Volatility
The U.S. stock market is once again sending signals of caution, as major indices experienced a notable pullback from their recent record highs in early September 2025. This downturn, following a robust... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
AstraZeneca's Latest Drug Offers Hope For Millions Battling Hard-To-Control Blood Pressure ↗
AstraZeneca's Baxdrostat met all endpoints in a Phase 3 trial, showing sustained blood pressure reductions in patients with resistant hypertension. 
Via Benzinga
News headline image
Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III ​trial
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca's $80 Billion Ambition Just Got A Big Infusion With New Hypertension Results ↗
AstraZeneca, on Saturday, unveiled promising results for a new hypertension treatment that aims to help the roughly 650,000 people. 
Via Investor's Business Daily
News headline image
Looking Into AstraZeneca's Recent Short Interest ↗
 
Via Benzinga
News headline image
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Regeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data ↗
Regeneron's Phase 3 NIMBLE trial showed cemdisiran improved myasthenia gravis symptoms, with an FDA filing expected in early 2026. 
Via Benzinga
News headline image
BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up ↗
BeOne Medicines will sell global Imdelltra royalties to Royalty Pharma for up to $950 million while retaining rights to other oncology programs with Amgen. 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
UK Drug Pricing Talks Collapse, Drugmakers Reject Offer Citing 'Uncompetitive' System ↗
UK drug pricing talks collapsed after the government and pharma firms failed to agree on National Health Service rebates. 
Via Benzinga
News headline image
J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs ↗
Johnson & Johnson (NYSE: JNJ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs... 
Via Benzinga
Topics Government World Trade
News headline image
IonQ Expands Quantum IP Portfolio, Surpassing 1,000 Patents And Applications ↗
IonQ, Inc. announces major progress in its IP strategy with new U.S. patents, reinforcing its leadership in quantum computing and potential for commercial advantage. 
Via Benzinga
Topics Intellectual Property
News headline image
AstraZeneca Launches Home Delivery Service For Its Self-Administrable Flu Vaccine ↗
Flumist can be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals 2-17 years of age. 
Via Stocktwits
News headline image
FLUMIST (Influenza, Vaccine Live, Intranasal), the nation’s only nasal spray flu vaccine, now available for home delivery
From AstraZeneca
Via Business Wire
News headline image
White House Eyes Up to 250% Drug Tariffs In Bid To Reclaim US Pharma Supply Chain ↗
White House trade adviser Peter Navarro discusses tariffs on pharma imports under a "Section 232" trade investigation. 
Via Benzinga
Topics World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.